ClinicalTrials.gg
RecruitingNCT05701917DEFIANCEUpdated Nov 3, 2026

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

An interventional study of ClotTriever System and Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. in Venous Thromboembolism, Deep Venous Thrombosis and Post-Thrombotic Syndrome, sponsored by Inari Medical. Recruiting at 64 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Inari Medical (part of Stryker) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 221 studies in Venous Thromboembolism with a site in United States — 37 open to participants now, 40 under way, 8 of them phase 3. Venous Thromboembolism · United States.

Planned enrollment
74th of 165
300 · median 218
Started
2023
with 10 others
No phase
40 of 221
6 open now
Primary completion
2028-01
later than 26 of 39 live
Registered
186th of 221
by date

Among the 221 studies in Venous Thromboembolism with a site in United States, this one is the 74th largest by planned enrollment of the 165 interventional ones that give a count, is one of 11 that started in 2023, is one of 40 with no phase, reaches primary completion later than 26 of the 39 other live ones, and was the 186th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

37 of the 221 studies in Venous Thromboembolism with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Venous Thromboembolism with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.

Read the detailed description

The study will compare the clinical outcomes of patients treated with an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of symptomatic unilateral iliofemoral DVT. Approximately 300 subjects will be enrolled and randomized. All subjects who sign informed consent and who meet all of the inclusion criteria and none of the exclusion criteria will be randomized (1:1, ClotTriever Intervention Arm or Conservative Medical Management Arm).

03

Conditions studied

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • Post-Thrombotic Syndrome

Keywords

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • Post-Thrombotic Syndrome
  • Anticoagulation
  • Percutaneous Mechanical Thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Proximal lower extremity unilateral DVT involving at least the common femoral, external iliac, or common iliac veins, alone or in combination
  • Symptom onset within 12 weeks of enrollment in the study
  • Significant symptoms, as defined by a Villalta score > 9
  • Willing and able to provide

Exclusion criteria

Exclusion Criteria

  • Bilateral iliofemoral DVT
  • Prior venous stent in the target venous segment
  • IVC aplasia/hypoplasia or other congenital anatomic anomalies of the IVC or iliac veins
  • IVC filter in place at the time of enrollment
  • Limb-threatening circulatory compromise (e.g., phlegmasia)
  • Clot in transit including IVC thrombus presenting as extension of >2cm into the IVC from the CIV
  • Symptomatic PE with right heart strain where the physician judges that a DVT intervention is inappropriate at this time.
  • Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
  • Severe allergy, to, or thrombocytopenia from heparin
  • Severe allergy to iodinated contrast agents that cannot be mitigated
  • \< 8.0 g/dL, > 1.7 before warfarin was started, or \< 50,000/µl which cannot be corrected prior to enrollment
  • Severe renal impairment (estimated \< 30 ml/min) in patients who are not yet on dialysis
  • Inability to provide therapeutic anticoagulation per Investigator discretion
  • Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
  • Recently (\< 30 days) had DVT interventional procedure
  • Subject is participating in another study that may interfere with this study
  • \< 6 months or chronic non-ambulatory status
  • Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
  • Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., to use of ClotTriever per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)
  • Subject has previously completed or withdrawn from this study
  • Patient unwilling or unable to conduct the follow up visits per protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Interventional

    Interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm).

    Device: ClotTriever System

  • Active comparator
    Conservative Medical Management

    Conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm).

    Drug: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

Interventions

  • DeviceClotTriever System

    Mechanical thrombectomy

  • DrugCommercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

    Anticoagulants are a group of medications that decrease your blood's ability to clot.

06

What researchers measure

Primary outcomes

  1. Composite clinical endpoint constructed as a win ratio, a hierarchy of the following:

    1. Occurrence of treatment failure or therapy escalation 2. Assessment of PTS severity, as defined by the Villalta scale

    Time frame: 180 Days (+-14 Days)

Secondary outcomes

  1. Composite clinical endpoint constructed as a win ratio, a hierarchy of the following:

    1. Vessel compressibility assessed by duplex ultrasound 2. Pain as assessed by the NPRS 3. An improvement of edema as assessed by leg calf circumference measurements

    Time frame: 10 Days (+- 3 Days)

  2. Assessment of PTS Severity:

    a. Assessment of PTS severity, as defined by the Villalta scale

    Time frame: 180 Days (+-14 Days)

07

Study locations

48 of 64 sites recruiting
  • Honor Health
    Scottsdale, Arizona 85258, United States
    Recruiting
    • Venkataramanan Gangadharan, MD · Contact
  • Pima Heart and Vascular
    Tucson, Arizona 85704, United States
    Recruiting
    • Joseph Sabat, MD · Contact
  • UCI Medical Center
    Orange, California 92868, United States
    Recruiting
    • Anthony H Chau, MD · Contact
  • Vascular and Interventional Specialists of Orange County
    Orange, California 92868, United States
    Recruiting
    • Theodore Bryan, MD · Contact
  • Huntington Health
    Pasadena, California 91105, United States
    Recruiting
    • Theodore Teruya, MD · Contact
  • University Of Colorado
    Denver, Colorado 80045, United States
    Recruiting
    • Jonathan D Lindquist, MD · Contact
  • Yale University
    New Haven, Connecticut 06520, United States
    Recruiting
    • Hamid R Mojibian, MD · Contact
  • MedStar Health Research Institution
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Saher S Sabri, MD · Contact
  • Manatee Memorial Hospital
    Bradenton, Florida 34208, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Baptist Health Research Institute
    Jacksonville, Florida 32207, United States
    Recruiting
    • Bharat Gummadi, MD · Contact
  • Lakeland Vascular Institute
    Lakeland, Florida 33805, United States
    Terminated

    Not enrolling at this site — choose another above.

  • HCA Florida Largo Hospital
    Largo, Florida 33770, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
    Recruiting
    • Juan C Camacho-Vasquez, MD · Contact
  • BayCare Health System
    Tampa, Florida 33607, United States
    Recruiting
    • Nicholas Turman, MD · Contact
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Community Healthcare System
    Munster, Indiana 46321, United States
    Terminated

    Not enrolling at this site — choose another above.

  • St. Elizabeth Edgewood
    Edgewood, Kentucky 41017, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Maryland
    Baltimore, Maryland 21201, United States
    Recruiting
    • Khanjan Nagarsheth, MD · Contact
  • McLaren Healthcare
    Bay City, Michigan 48708, United States
    Recruiting
    • Nicolas Mouawad, MD · Contact
  • Henry Ford Health
    Detroit, Michigan 48202, United States
    Recruiting
    • Scott Kaatz, MD · Contact
  • MyMichigan Medical Center
    Midland, Michigan 48670, United States
    Recruiting
    • Contantinos Constantinou, MD · Contact
  • University of Missouri
    Columbia, Missouri 65212, United States
    Recruiting
    • Ambarish Bhat, MD · Contact
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64131, United States
    Terminated

    Not enrolling at this site — choose another above.

  • St. Louis University
    St Louis, Missouri 63104, United States
    Recruiting
    • Keith Pereira, MD · Contact
  • University Medical Center of Southern Nevada
    Las Vegas, Nevada 89102, United States
    Recruiting
    • Ryan Rimer, MD · Contact
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
    Recruiting
    • Laurel Hastings, MD · Contact
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Northwell Health
    Bay Shore, New York 11706, United States
    Recruiting
    • Jonathan A Schor, MD · Contact
  • NYP-Brooklyn Methodist
    Brooklyn, New York 11215, United States
    Recruiting
    • Rajesh K Malik, MD · Contact
  • SUNY, The University at Buffalo
    Buffalo, New York 14203, United States
    Terminated

    Not enrolling at this site — choose another above.

  • NYU Langone Medical Center
    New York, New York 10016, United States
    Recruiting
    • Katherine Teter, MD · Contact
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
    • Edvard Skripochnik, MD · Contact
  • Mission Health
    Asheville, North Carolina 28801, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Mercy Health - The Heart Institute
    Cincinnati, Ohio 45211, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Aravinda Nanjundappa, MD · Contact
  • Saint Francis Hospital
    Tulsa, Oklahoma 74136, United States
    Recruiting
    • Tucker J Harrison, DO · Contact
  • Allegheny St. Vincent Hospital
    Erie, Pennsylvania 16544, United States
    Recruiting
    • Orestis Pappas, MD · Contact
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Robert W Ford, MD · Contact
  • Allegheny General Health Research Network
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Abdullah A Shaikh, MD · Contact
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
    Recruiting
    • John Lee, MD · Contact
  • Prisma Health Upstate
    Greenville, South Carolina 29615, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Spartanburg Medical Center
    Spartanburg, South Carolina 29303, United States
    Recruiting
    • Brian J Brown, MD · Contact
  • Lexington Medical Center
    West Columbia, South Carolina 29169, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Mark D Iafrati, MD · Contact
  • Clements University Hospital (UTSW)
    Dallas, Texas 75390, United States
    Recruiting
    • Michael C Siah, MD · Contact
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
    Recruiting
    • David J Dexter, MD · Contact
  • Providence Sacred Heart Med Center
    Spokane, Washington 99204, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Vienna General Hospital (AKH Wien)
    Vienna, Austria
    Recruiting
    • Oliver Schlager, Dr. med · Contact
  • Helsinki University Hospital
    Helsinki, Finland
    Recruiting
    • Matti Laine, MD, PhD · Contact
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Würtemberg 72076, Germany
    Recruiting
    • Gerd Grözinger, Dr. med. · Contact
  • MVZ CCB Frankfurt und Main-Taunus GbR
    Frankfurt am Main, Hesse 60389, Germany
    Recruiting
    • Michael Piorkowski, Dr. med. · Contact
  • Klinikum Hochsauerland GmbH
    Arnsberg, North Rhine-Westphalia 59759, Germany
    Recruiting
    • Michael Lichtenberg, MD · Contact
  • Universität Leipzig
    Leipzig, Saxony 04109, Germany
    Recruiting
    • Andrej Schmidt, Prof Dr med · Contact
  • Charité - Universitätsmedizin Berlin
    Berlin, State of Berlin 10117, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Augsburg
    Augsburg, Germany
    Recruiting
    • Christian Scheurig-Münkler, PD Dr. · Contact
  • Universitätsklinikum Heidelberg
    Heidelberg, Germany
    Recruiting
    • Christian Erbel, Prof. Dr. · Contact
  • Kantonsspital Baden
    Baden, Switzerland
    Recruiting
    • Michael Kostrzewa, Dr. · Contact
  • Inselspital, Universitätsspital Bern
    Bern, Switzerland
    Recruiting
    • Marc Schindewolf, Dr. med. · Contact
  • Luzerner Kantonsspital
    Lucerne, Switzerland
    Recruiting
    • Thorsten Grumann, Dr. med. · Contact
  • GSST London/St Thomas
    London, United Kingdom
    Recruiting
    • Taha Khan, Mr · Contact
  • Imperial College
    London, United Kingdom
    Recruiting
    • Alun H Davies, Prof. · Contact
  • Freeman Hospital Newcastle upon Tyne
    Newcastle upon Tyne, United Kingdom
    Recruiting
    • Sandip Nandhra, Dr. · Contact
  • Oxford - John Radcliffe
    Oxford, United Kingdom
    Recruiting
    • Andrew Wigham, Dr · Contact
08

References and documents

Publications

  • Abramowitz SD, Marko X, D'Souza D, Noor S, Pereira K, Silver MJ, Rosenberg SP, Markovitz CD, Tu T, Weinberg I, Black S. Rationale and design of the DEFIANCE study: A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosis. Am Heart J. 2025 Mar;281:92-102. doi: 10.1016/j.ahj.2024.10.016. Epub 2024 Nov 3. PubMed 39491572 ↗
  • Flumignan RL, Nakano LC, Flumignan CD, Baptista-Silva JC. Angioplasty or stenting for deep venous thrombosis. Cochrane Database Syst Rev. 2025 Feb 19;2(2):CD011468. doi: 10.1002/14651858.CD011468.pub2. PubMed 39968829 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2028, 60 months after the start.

Of 70 interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 27, 2023
StartActual
Jan 6, 2023
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05701917
Lead sponsor
Inari Medical
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Jan 6, 2023
Primary completion
Jan 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Mark Sung
Contact
mark.sung@stryker.com
949-466-9458
Sara Willis
Contact
sara.willis@stryker.com
Steven Abramowitz, MD
principal investigator · MedStar Health Research Institution
Xhorlina Marko, MD
principal investigator · Henry Ford Health
Stephen Black, MD
principal investigator · St Thomas' Hospital (UK)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion